Drug Profile


Alternative Names: SPC 101210

Latest Information Update: 30 Jun 1998

Price : $50

At a glance

  • Originator Research Triangle Park Laboratories
  • Class Acetamides; Antineoplastics; Antipsoriatics; Small molecules
  • Mechanism of Action Protein kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Psoriasis

Most Recent Events

  • 30 Jun 1998 Discontinued - Preclinical for Psoriasis in USA (unspecified route)
  • 30 Jun 1998 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 28 Feb 1995 Preclinical development for Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top